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That each of us is truly biologically unique, extending to even monozygotic, ‘‘identical’’ twins, is not
fully appreciated. Now that it is possible to perform a comprehensive ‘‘omic’’ assessment of an
individual, including one’s DNA and RNA sequence and at least some characterization of one’s
proteome, metabolome, microbiome, autoantibodies, and epigenome, it has become abundantly
clear that each of us has truly one-of-a-kind biological content. Well beyond the allure of thematch-
less fingerprint or snowflake concept, these singular, individual data and information set up a
remarkable and unprecedented opportunity to improve medical treatment and develop preventive
strategies to preserve health.From Digital to Biological to Individualized Medicine
In 2010, Eric Schmidt of Google said ‘‘The power of individual
targeting—the technology will be so good it will be very hard
for people to watch or consume something that has not in
some sense been tailored for them’’ (Jenkins, 2010). Although
referring to the capability of digital technology, we have now
reached a time of convergence of the digital and biologic do-
mains. It has been well established that 0 and 1 are interchange-
able with A, C, T, and G in books and Shakespeare sonnets and
that DNA may represent the ultimate data storage system
(Church et al., 2012; Goldman et al., 2013b). Biological transis-
tors, also known as genetic logic gates, have now been devel-
oped that make a computer from a living cell (Bonnet et al.,
2013). The convergence of biology and technology was further
captured by one of the protagonists of the digital era, Steve
Jobs, who said ‘‘I think the biggest innovations of the 21st cen-
tury will be at the intersection of biology and technology. A
new era is beginning’’ (Issacson, 2011).
With whole-genome DNA sequencing and a variety of omic
technologies to define aspects of each individual’s biology at
many different levels, we have indeed embarked on a new era
of medicine. The term ‘‘personalized medicine’’ has been used
for many years but has engendered considerable confusion. A
recent survey indicated that only 4% of the public understand
what the term is intended tomean (Stanton, 2013), and the hack-
neyed, commercial use of ‘‘personalized’’ makes many people
think that this refers to a concierge service of medical care.
Whereas ‘‘person’’ refers to a human being, ‘‘personalized’’
can mean anything from having monogrammed stationary or
luggage to ascribing personal qualities. Therefore, it was not
surprising that a committee representing the National Academy
of Sciences proposed using the term ‘‘precision medicine’’ as
defined by ‘‘tailoring of medical treatment to the individual char-
acteristics of each patient’’ (National Research Council, 2011).
Although the term ‘‘precision’’ denotes the objective of exact-
ness, ironically, it too can be viewed as ambiguous in this contextbecause it does not capture the sense that the information is
derived from the individual. For example, many laboratory tests
could be made more precise by assay methodology, and treat-
ments could be made more precise by avoiding side effects—
without having anything to do with a specific individual. Other
terms that have been suggested include genomic, digital, and
stratified medicine, but all of these have a similar problem or
appear to be too narrowly focused.
The definition of individual is a single human being, derived
from the Latin word individu, or indivisible. I propose individual-
ized medicine as the preferred term because it has a useful
double entendre. It relates not only to medicine that is particular-
ized to a human being but also the future impact of digital
technology on individuals driving their health care. There will
increasingly be the flow of one’s biologic data and relevant
medical information directly to the individual. Be it a genome
sequence on a tablet or the results of a biosensor for blood pres-
sure or another physiologic metric displayed on a smartphone,
the digital convergence with biology will definitively anchor the
individual as a source of salient data, the conduit of information
flow, and a—if not the—principal driver of medicine in the future.
The Human GIS
Perhaps the most commonly used geographic information
systems (GIS) are Google maps, which provide a layered
approach to data visualization, such as viewing a location via
satellite overlaid with street names, landmarks, and real-time
traffic data. This GIS exemplifies the concept of gathering and
transforming large bodies of data to provide exquisite temporal
and location information. With the multiple virtual views, it gives
one the sense of physically being on site. Although Google has
digitized and thus created a GIS for the Earth, it is now possible
to digitize a human being. As shown in Figure 1, there are multi-
ple layers of data that can now be obtained for any individual.
This includes data from biosensors, scanners, electronic medi-
cal records, social media, and the various omics that includeCell 157, March 27, 2014 ª2014 Elsevier Inc. 241
Figure 1. Geographic Information System of a Human Being
The ability to digitize the medical essence of a human being is predicated on
the integration of multiscale data, akin to a Google map, which consists of
superimposed layers of data such as street, traffic, and satellite views. For a
human being, these layers include demographics and the social graph, bio-
sensors to capture the individual’s physiome, imaging to depict the anatomy
(often along with physiologic data), and the biology from the various omics
(genome-DNA sequence, transcriptome, proteome, metabolome, micro-
biome, and epigenome). In addition to all of these layers, there is one’s
important environmental exposure data, known as the ‘‘exposome.’’DNA sequence, transcriptome, proteome, metabolome, epige-
nome, microbiome, and exposome. Going forward, I will use
the term ‘‘panoromic’’ to denote the multiple biologic omic
technologies. This term closely resembles and is adopted from
panoramic, which refers to a wide-angle view or comprehensive
representation across multiple applications and repositories. Or
more simply, according to the Merriam-Webster definition of
panoramic, it ‘‘includes a lot of information and covers many
topics.’’ Thus the term panoromic may be well suited for portray-
ing the concept of big biological data.
The first individual who had a human GIS-like construct was
Michael Snyder. Not only was his whole genome sequenced,
he also collected serial gene expression, autoantibody, proteo-
mic, and metabolomic (Chen et al., 2012) samples. A portion of
the data deluge that was generated is represented in the Circos
plot of Figure 2 or an adoption of the London Tube map (Shen-
dure and Lieberman Aiden, 2012). The integrated personal omics
profiling (iPOP) or ‘‘Snyderome,’’ as it became known, proved to
be useful for connecting viral infections to markedly elevated
glucose levels. With this integrated analysis in hand, Michael
Snyder changed his lifestyle, eventually restoring normal glucose
homeostasis. Since that report in 2012, Snyder and his team
have proceeded to obtain further omic data, including whole-
genome DNA methylation data at multiple time points, serial
microbiome (gut, urine, nasal, skin, and tongue) sampling, and
the use of biosensors for activity tracking and heart rhythm.
Snyder also discovered that several extended family members
had smoldering, unrecognized glucose intolerance, thereby
changing medical care for multiple individuals.
Of note, to obtain the data and process this first panoromic
study, it required an armada of 40 experienced coauthors and242 Cell 157, March 27, 2014 ª2014 Elsevier Inc.countless hours of bioinformatics and analytical work. To give
context to the digital data burden, it took 1 terabyte (TB) for
DNA sequence, 2 TB for the epigenomic data, 0.7 TB for the
transcriptome, and 3 TB for the microbiome. Accordingly, this
first human GIS can be considered a remarkable academic
feat and yielded key diagnostic medical information for the
individual. But, it can hardly be considered practical or scalable
at this juncture. With the cost of storing information continuing to
drop substantially, the bottleneck for scalability will likely be
automating the analysis. On the other hand, each omic technol-
ogy can readily be undertaken now and has the potential of
providing meaningful medical information for an individual.
The Omic Tools
Whole-Genome and Exome Sequencing
Perhaps the greatest technologic achievement in the biomedical
domain has been the extraordinary progress in our ability to
sequence a human genome over the past decade. Far exceeding
the pace of Moore’s Law for the relentless improvement in tran-
sistor capacity, there has been a >4 log order (or 0.00007th)
reduction in cost of sequencing (Butte, 2013), with a cost in
2004 of $28.8 million compared with the cost as low as
$1,000 in 2014 (Hayden, 2014). However, despite this incompa-
rable progress, there are still major limitations to how rapid,
accurate, and complete sequencing can be accomplished.
High-throughput sequencing involves chopping the DNA into
small fragments, which are then amplified by PCR. Currently, it
takes 3 to 4 days in our lab to do the sample preparation and
sequencing at 303 to 403 coverage of a human genome. The
read length of the fragments is now 250 base pairs for the
most cost-effective sequencing methods, but this is still subop-
timal in determining maternal versus paternal alleles, or what
is known as phasing. Because so much of understanding dis-
eases involves compound heterozygote mutations, cis-acting
sequence variant combinations, and allele-specific effects,
phasing the diploid genome, or what we have called ‘‘diplomics’’
(Tewhey et al., 2011), is quite important. Recently, Moleculo
introduced a method for synthetically stitching together DNA
sequencing reads yielding fragments as long as 10,000 base
pairs. These synthetic long reads are well suited for phasing. Un-
fortunately, the term ‘‘whole-genome sequencing’’ is far from
complete because 900 genes, or 3%–4% of the genome, are
not accessible (Marx, 2013). These regions are typically in cen-
tromeres or telomeres. Other technical issues that detract from
accuracy include long sequences of repeated bases (homopoly-
mers) and regions rich in guanine and cytosine. Furthermore, the
accuracy for medical grade sequencing still needs to be
improved. A missed call rate of 1 in 10,000, which may not
seem high, translates into a substantial number of errors when
considering the 6 billion bases in a diploid genome. These errors
obfuscate rare but potentially functional variants. Beyond this
issue, the accurate determination of insertions, deletions, and
structural variants is impaired, in part due to the relatively
short reads that are typically obtained. The Clinical Sequencing
Exploratory Research (CSER) program at the National Institutes
of Health is aimed at improving the accuracy of sequencing for
medical applications (National Human Genome Research Insti-
tute, 2013).
Figure 2. Plots of Panoramic Information
Top: Circos plot of the Snyder genome. From outer
to inner rings: chromosome ideogram; genomic
data (pale blue ring), structural variants >50 bp
(deletions [blue tiles], duplications [red tiles]),
indels (green triangles); transcriptomic data
(yellow ring), expression ratio of viral infection to
healthy states; proteomic data (light purple ring),
ratio of protein levels during human rhinovirus
(HRV) infection to healthy states; transcriptomic
data (yellow ring), differential heteroallelic
expression ratio of alternative allele to reference
allele for missense and synonymous variants
(purple dots) and candidate RNA missense and
synonymous edits (red triangles, purple dots,
orange triangles, and green dots, respectively).
From Chen et al. (2012) with permission.
Bottom: Adopted London Tube model of inte-
grated omics fromShendure and Aiden Integration
of the many applications of next-generation DNA
sequencing, which include sites of DNA methyl-
ation (methyl-seq), protein-DNA interactions
(ChIP-seq), 3D genome structure (Hi-C), geneti-
cally targeted purification of polysomal mRNAs
(TRAP), the B cell and T cell repertoires (immuno-
seq), and functional consequences of genetic
variation (synthetic saturation mutagenesis) with a
small set of core techniques, represented as open
circles of ‘‘stations.’’ Like subway lines, individual
sequencing experiments move from station to
station until they ultimately arrive at a common
terminal—DNA sequencing.
From Shendure and Lieberman Aiden (2012) with
permission.Despite these shortcomings, the ability to identify rare or low-
frequency variants that are pathogenic has been a major
outgrowth of high-throughput sequencing. Well beyond the
genome scans and genome-wide association studies that
identified common variants associated with most complex,
polygenic diseases and human traits, sequencing leads to high
definition of the uncommon variants that typically have much
higher penetrance. For example, rare Mendelian conditionsCell 15have seen a remarkable surge of defini-
tion of their genomic underpinnings
(Boycott et al., 2013). In the first half of
2010, the basis for four rare diseases
was published, but in the first half of
2012, that number jumped to 68 (Boycott
et al., 2013). With the power of
sequencing, it is anticipated that the
molecular basis for most of the 7,000
known Mendelian diseases will be unrav-
eled in the next few years.
The 1.5% versus 98.5% Genome
Sequencing Dilemma
The exome consists of only 40 Mb, or
1.5% of the human genome. There is
continued debate over the use of whole-
exome sequencing compared with
whole-genome sequencing, given the
lower cost of sequencing an exome,
that can be readily captured via kitsfrom a few different companies (Agilent SureSelect, Illumina
TruSeq, and Roche NimbleGen). Exome sequencing is typically
performed at much deeper coverage, >1003 (as compared with
303–403 for whole genome), which enhances accuracy, and
the interpretation of variants that affect coding elements is far
more advanced compared with the rest of the genome. How-
ever, the collective output from genome-wide association
studies of complex traits has indicated that 80% of the7, March 27, 2014 ª2014 Elsevier Inc. 243
Figure 3. Hypothetical Plot of Cost of Sequencing and Number of
Individuals Sequenced over the Next 6 Years
As of early 2014, <100,000 individuals have had whole-genome sequencing,
leaving the information difficult to fully interpret (of limited informativeness or
value). When millions of people undergo sequencing, with the full gamut of
diverse phenotypes and ancestries, and the cost for sequencing continues to
drop, a virtuous cycle of informativeness is established. With the new capa-
bility in 2014 to have whole-genome sequencing at a cost of $1,000, along with
extremely high throughput, it is likely that millions of individuals will be
sequenced in the next 3–4 years. The cost of sequencing will continue to drop
throughout this time, as increasing numbers of individuals undergo
sequencing. Projections suggest that at least 20,000 individuals with each
phenotype may be necessary to reliably identify rare, functional genomic
variants. Accordingly, once millions of individuals across all main phenotypes
and ancestries are sequenced, there is a new set point, or threshold, of
informativeness.incriminated loci are in noncoding regions, outside the confines
of genes (Koboldt et al., 2013). It is fair to say that we have long
underestimated the importance of the rest of the genome, but its
high density of key regulatory features provides intricate and
extraordinarily tight control over how genes operate. Recent
whole-genome sequencing studies have identified many critical
variants in noncoding portions of the genome (Khurana et al.,
2013). A typical whole human genome sequence will contain
3.5 million variants compared with the reference genome, pre-
dominantly composed of single-nucleotide polymorphisms but
also including insertion-deletions, copy number variants, and
other types of structural variants (Frazer et al., 2009). Today,
analysis of most of the 3.5 million variants is left with the ‘‘variant
of unknown significant’’ (VUS) diagnosis. As more people get
sequenced with the full range of disease phenotypes, the pro-
portion of VUS will drop, and each sequence will become more
informative. Figure 3 provides a theoretical plot of how further
reduction of the cost of whole-genome sequencing will also be
accompanied by large numbers of individuals undergoing
sequencing. In 2014, still well under 100,000 people have had
whole-genome sequencing with only a very limited number of
phenotypes addressed. At some point in the future, sequence
data get progressively more informative at a lower price point,
thus establishing particular value of whole-genome sequencing.
It is not just about getting a large number of people with diverse
medical conditions and diverse ancestries sequenced. The drive
to informativeness will clearly be enhanced by incorporating
family genomic assessment, especially for determining whether244 Cell 157, March 27, 2014 ª2014 Elsevier Inc.rare variants are meaningful. Here, too much focus on the indi-
vidual can result in a loss of context, back to our analogy of
the Google map of maximal zoom obscuring understanding.
By anchoring the genomics of family members, such as was
done with the important discovery of PCSK9 rare variants (Hall,
2013) in cholesterol metabolism, progress in genomic medicine
will be catalyzed.
At this juncture, however, it appears that exome and whole-
genome sequencing provide complementary information. As
the cost of whole-genome sequencing is further reduced, along
with the availability of enhanced analytical tools for the nongene
98.5% content interpretation, exome sequencing may ultimately
become obsolete.
Single-Cell Sequencing
The ability to perform sequencing of individual cells has provided
remarkable new insights about human biology and disease
(Shapiro et al., 2013; Battich et al., 2013; Owens, 2012). The un-
expected heterogeneity in DNA sequence from one cell to
another, such as has been well documented in tumor tissue
and even in somatic cells in healthy individuals, has enlightened
us about intraindividual genomic variation. The concept of
‘‘mosaicism’’ has gained rapid acceptance—with multiple
mechanisms—ranging from gamete formation, embryonic
development, to somatic mutation in cells in adulthood, that
account for why each of us has cells with different DNA
sequences (Lupski, 2013; Wang et al., 2012; Macosko and
McCarroll, 2012; Poduri et al., 2013). It remains unclear whether
mosaicism has functional significance beyond being tied to
certain congenital conditions and cancers, but this is an active
area of research that is capitalizing on single-cell sequencing
technology. This is especially the case in neuroscience in order
to explain the observed frequent finding of transposons, which
appear to involve between 80 and 300 unique insertions for
each neuron and are potentially associated with neurologic dis-
eases (Poduri et al., 2013).
Sperm, which tend to swim solo, are particularly well suited
for single-cell genomics. This work has quantified recombination
rates of 25 events per sperm, identified the hot spots
where these events are most likely to occur, and determined
genomic instability as reflected by the rate of de novo mutations
(Wang et al., 2012; Poduri et al., 2013). Such de novo mutations,
which increase in sperm with paternal age, are associated with
autism, schizophrenia, and intellectual disability (Poduri et al.,
2013; Kong et al., 2012; Veltman and Brunner, 2012; de Ligt
et al., 2012).
Intriguing, and possibly revolutionary, single-cell methods
using in situ sequencing protocols are set to offer precise
spatial information in addition to linear sequence data. In situ
sequencing holds the potential to resolve the spatial distribution
of copy number variants, circular DNA, tumor heterogeneity, and
RNA localization. A number of methods have been published in
the last year, and progress is likely to accelerate in the near
future.
Transcriptomics, Proteomics, and Metabolomics
As opposed to the DNA sequence, which is relatively static, RNA
reflects the dynamic state of the cell. Gene expression of a
particular tissue of the whole genome has been available via
microarrays for several years, but RNA sequencing (RNA-seq)
is a relatively new tool that transcends simple expression by
capturing data on gene fusions, alternative spliced transcripts,
and posttranscriptional changes, along with the whole gamut
of RNAs (including microRNA [e.g., miRNAseq], small RNA,
lincRNA, ribosomal RNA, and transfer RNA).
A particularly valuable metric related to RNA is the expression
quantitative trait locus (eQTL). By having both genome-wide
association study (GWAS) data and whole-genome gene
expression at baseline with or without particular stimuli, func-
tional genomic assessment has been enabled. For example,
Westra et al. (2013) used eQTLs and loci derived from GWAS
to provide functional genomic, mechanistic insights for multiple
complex traits, including lupus and type 1 diabetes.
The proteome, metabolome, and autoantibody landscape can
be assessed for an individual approaching the whole-genome
level via recent advances in mass spectrometry and protein
arrays. Using these techniques, posttranslational modifications
of proteins, protein-protein interactions, or the small-molecule
metabolites produced by these proteins can be revealed.
Emerging technologies such as RNA-mediated oligonucleotide
annealing, selection, and ligation sequencing (RASL-seq),
barcoded small hairpin RNA (shRNA) libraries, and combinatorial
antibody libraries provide inexpensive and efficient views of
biology. Longer read sequencing provides the opportunity to
sequence antibodies, which typically have variable and constant
regions composed of 2,000 nucleotides.
Microbiome
Perhaps no area of biology has received more attention in recent
years than the microbiome. Just the gut microbiome has orders
of magnitude more DNA content than germline human DNA and
has markedly heightened diversity. Our commensal bacterial
flora has been shown to play an important role in various medical
conditions (Cho and Blaser, 2012). From fecal samples using a
16S ribosomal amplicon sequencing method, the gut micro-
biome has been the subject of intensive prospective clinical
assessment. It was determined that there were three major
enterotypes of the intestinal microbiome based on the predom-
inant bacterial species, such as Bacteroides, Ruminococcus, or
Prevotella (Arumugam et al., 2011). The resident species appear
to be quite stable over an extended period of time and to be
initially transmitted via the mother at childbirth (Faith et al.,
2013). As the interface between genomics and the host’s envi-
ronment, the microbiome clearly plays a pivotal role in defining
each individual. The influence of the diet on the gut microbiome,
such as the content of fiber, along with the underpinning of
malnutrition, has been documented (Gordon et al., 2012; Ridaura
et al., 2013). For example, even an individual’s response to
medications, such as digoxin (Haiser et al., 2013), or multiple
drugs used for cancer, has been shown to be linked to the bac-
terial flora of the gut microbiome (Viaud et al., 2013; Iida et al.,
2013).
Epigenome
There has been extraordinary progress in our ability to map the
human epigenome from DNA methylation to histone modifica-
tions and chromatin structure (Ziller et al., 2013; Rivera and
Ren, 2013). The prolific ENCODE project has provided troves
of data detailing the role of regulatory elements such as en-
hancers and insulators and how they are tied to DNAmethylationand histone changes (Dawson and Kouzarides, 2012). Like gene
expression, epigenomic findings are highly cell-type specific,
with more than 200 different cell types in the human body. For
methylation, whole-genome bisulphite sequencing has recently
been performed for 30 diverse human cell types (Rivera and
Ren, 2013). Epigenomic reprogramming has a clear-cut role in
cancer, be it via transcription factors or chromatin regulators
(Dawson and Kouzarides, 2012; Suva` et al., 2013). Although
access to tissue to define epigenomic signatures is a limiting
factor outside of the cancer space, it is apparent that many other
diseases are affected by epigenomic dynamics, such as compli-
cations of diabetes, rheumatoid arthritis, or hypertension (Pirola
et al., 2010; Liu et al., 2013; Fratkin et al., 2012). Furthermore,
epigenomic changes affect susceptibility to diseases, as has
been shown with open chromatin related to the TCF7L2 gene
(Groop, 2010) and parental origin of sequence variants for
Type 2 diabetes mellitus and breast and prostate cancer (Kong
et al., 2009). This parent-of-origin issue may be tied to transge-
nerational epigenomic instability, as has been well documented
in plants, and is certainly a key element of human biology and
heritability (Schmitz et al., 2011).
Physiome and Exposome
Understanding and quantifying an individual’s physiology and
environmental interactions are crucial to digitizing a human
being. Through wearable biosensors and smartphones, this
has become eminently practical. Continuous tracking is now
obtainable for most key physiologic metrics, including blood
pressure, heart rhythm, glucose, blood oxygen saturation, brain
waves, intraocular eye pressure, and lung function indices.
Similarly, there are environmental sensors that connect with
smartphones to quantify such indices as air pollution, pollen
count, radiation, water quality, ambient humidity, electromag-
netic fields, and the presence of pesticides in food.
Bioinformatics
Fundamental to individualized medicine is the ability to analyze
the immense data sets and to extract all of the useful, salient
information. This is exemplified by the task of sifting through a
trio of whole-genome sequences to find a causative mutation
in a proband with an undiagnosed disease. Typically, this trans-
lates to finding one critical nucleotide variant out of well over one
to twomillion single base variants and simplifying the analysis by
only considering variants that change amino acid sequence or
lead to obvious splicing defects (Maher, 2011). Identifying the
signal from the noise, with the vast majority of variants catego-
rized as ‘‘unknown significance’’ (VUS), is the crux of the chal-
lenge. Moreover, the tools to assess structural variants and
indels are not as extensively developed and validated. So there
are considerably more data that come from the sequencer for
an individual than can be fully and accurately mined. Beyond
this, there is the need for better integration of the multiple GIS
layers, such as panoromic and biosensor data, and the ability
to provide an integrative multiscale approach to an individual’s
data set. Although not the comprehensive multilayer as depicted
in Figure 2, Zhang et al. (2013) recently used an integrated
systems approach, including omics of both human and mice
brains to discover genetic networks in Alzheimer’s disease.
Although in the past there were generally insufficient efforts
to understand epistasis, gene-gene interactions have beenCell 157, March 27, 2014 ª2014 Elsevier Inc. 245
Figure 4. Timeline of Sequencing Applica-
tions in Medicine from Prewomb to Tomb
The medical application of genomics is relevant to
many points during an individual’s lifespan. Prior
to conception, a couple can have genomic
screening for important recessive alleles. An
expectant mother, at 8–12 weeks of pregnancy,
can now have single tube of blood used to accu-
rately assess chromosomal abnormalities of the
fetus, determine gender, and even have whole-
genome sequencing of the fetus performed. At
birth, sequencing the genome of the newborn can
be used to rapidly diagnosis many critical condi-
tions for which a time delay, which frequently can
occur with the present heel stick screening
methods, might lead to irrevocable damage. The
molecular basis for serious, undiagnosed condi-
tions can often be established by sequencing the
individual with parents of siblings. Ultimately, omic
information at a young age will be useful by
providing susceptibility to various medical condi-
tions that have actionable prevention strategies.
Sequencing can be done to define a pathogen for
more rapid and accurate approaches to infectious diseases. The driver mutations and key biologic underpinning pathways of an individual’s cancer can
frequently be pinpointed by omics. The root causes of common polygenic conditions such as diabetes or coronary heart diseasemay ultimately be defined at the
individual level. Specific sequence variants of germline DNA or the gut microbiome have relevance for response to prescription medication (both efficacy and
safety). Defining the genomics of healthspan, rather than the traditional focus on diseases, may prove to be especially worthwhile to understand protective alleles
and modifier genes. For an individual with sudden death, a molecular autopsy via sequencing can be performed, along with family survivors, to determine the
cause of death and potentially prevent untimely or avoidable deaths of members of the family and subsequent generations.upstaged by the complexity of a higher-order bioinformatics
challenge.
How the Omic Tools Reboot Medicine
A Prewomb-to-Tomb Assessment
At many points in the span of a lifetime, the unique biology of
the individual will play an increasing role. As depicted in the time-
line of Figure 4, I will go through each topic sequentially.
Preconception
The ability to determine carrier mutations for each prospective
parent has been greatly enhanced through multiple direct-to-
consumer sources, including 23andMe, Counsyl, GenePeeks,
and Good Start Genetics. This can be considered the ultimate
form of prevention for major recessive conditions and has only
received modest attention to date. Counsyl screens for more
than 100 recessive Mendelian traits, and 23andMe screens
50 carrier conditions. The carrier rates for many serious condi-
tions are higher than most people would suspect, such as 1 in
35 for spinal muscular atrophy, 1 in 40 for cystic fibrosis, and 1
in 125 individuals for Fragile X syndrome (Test, 2013). Gene-
Peeks uses carrier data from 100,000 DNA sequence variants
for each prospective parent to perform a computer simulation
of 10,000 ‘‘digital babies,’’ determining the probabilistic odds
of significant Mendelian disorders (Couzin-Frankel, 2012).
They are already using their analytic methodology to screen
sperm from the Manhattan cryobank; until now, sperm banks
have been completely unregulated and without genomic
assessment (Almeling, 2013; Rincon, 2013). The concept of
higher DNA resolution preconception screening is attractive,
given that there are many more pathogenic variants in the
genes that are implicated in disease, such as cystic fibrosis
(2,000 variants), than are conventionally assessed (Sosnay
et al., 2013).246 Cell 157, March 27, 2014 ª2014 Elsevier Inc.Fetal Sequencing
Whereas the diagnosis of chromosomal aberrations such as
trisomy-21, 18, 13 required amniocentesis or chorionic villi
sampling, there are now four different maternal blood sampling
assays to accomplish the same assessment with extremely
high (>99%) accuracy (Morain et al., 2013). Relying on the
plasma fetal DNA present in adequate quantity from a maternal
blood sample at 8–10 weeks of pregnancy, such testing has
been transformative, preempting the need for amniocentesis in
all but the rare exception when results are ambiguous. Here is
a great example of using plasma-free DNA sequencing to avoid
an invasive test that carries a small but important risk of miscar-
riage. However, with more than 4 million births in the United
States each year, only a tiny fraction (<2%) of prenatal maternal
blood sampling has yet been performed in clinical practice.
Multiple groups have demonstrated the ability to do a fetal
whole-exome sequence from a maternal blood sample (Fan
et al., 2012) or whole-genome sequencing from both parents’
DNA along with the maternal plasma-free DNA (Kitzman et al.,
2012; Lo et al., 2010), but this takes a rather extensive computing
and bioinformatics effort that is not presently scalable. Un-
doubtedly, that will be resolved over time but will engender the
serious bioethical issues of what constitutes the appropriate
reasons for termination of pregnancy. But, at the same time, it
will afford the opportunity to make the molecular diagnoses of
conditions in utero and facilitate treatment then or at the earliest
time after birth.
Neonatal Sequencing
Monogenic diseases, many of which present in the first month of
life, are a major cause of neonatal fatality and morbidity (Saun-
ders et al., 2012). Despite routine heel sticks for blood sent out
for analysis, with attendant delays of several days to weeks in
obtaining results, there has not been any improvement in
Figure 5. Legend from Whole-Genome Sequencing to Identification
of a Causative Variant
Following sequencing, alignment, and annotation, the 3.5 million variants—all
genetic variants in the family (unaffected and affected individuals)—are
analyzed to identify known disease variants. Then inheritance-based and
population-based filters are applied. Phenotype-informed ranking and func-
tional filters are used to then determine the root-cause variant. The timeline for
this involves (1) sample preparation of 2 days, (2) sequencing of 2 days in fast
output mode, the (3) preliminary analysis in24 hr (6 hr for variant calling, 1 hr
annotation, 1 hr for each candidate variant), and (4) literature review to exclude
and include genes hit by potential candidate variants—an additional 5 days.
The cost for analysis is predominantly personnel and compute time on the
cloud, estimated to be $300.reducing neonatal mortality related to genetic disorders in the
past 20 years (Kaiser, 2013; Sosnay et al., 2013). Now, it has
been shown that whole-genome sequencing of newborns can
be accomplished in <48 hr and can lead to highly actionable
information for managing a neonate’s condition, such as in the
classic example of phenylketonuria or galactosemia, whereby
irrevocable damage might otherwise occur (Saunders et al.,
2012; Kaiser, 2013; Sosnay et al., 2013).
Undiagnosed, Idiopathic, and Rare Diseases
The diagnosis of an XIAP mutation in a child with fulminant pan-
colitis with successful, curative treatment is often cited as the
first case of sequencing to save an individual’s life (Worthey
et al., 2011). Since that report, there have been several other
cases that used whole-genome or exome sequencing, along
with other omic tools, for making the molecular diagnosis of idio-
pathic conditions (Jacob et al., 2013). For example, the National
Institutes of Health Undiagnosed Disease Program uses exome
sequencing to facilitate the diagnosis (Gahl and Tifft, 2011).
Recently, the group at Baylor College of Medicine published a
series of 250 individuals, of whom 80% were pediatric and
largely affected by neurologic conditions, who underwent
whole-exome sequencing. In that cohort, there were many
affected patients with a known Mendelian trait but without a
specific root cause established. A molecular diagnosis was
made in 25% of the cohort (Yang et al., 2013). At the Scripps
Health and Scripps Research Institute, we have screened morethan 100 individuals for the potential of having an idiopathic
disease. This requires review by a multidisciplinary physician
panel to assure that a comprehensive evaluation of the patient
has been performed before turning to DNA sequencing. The first
of 15 individuals who we enrolled into our protocol was 16 years
old and had an incapacitating neurologic condition. She and her
parents were sequenced, and in Figure 5, the bioinformatics
challenge of interpreting the three whole-genome sequences is
presented, along with the molecular diagnosis of an ADCY5
mutation that had not been previously described. In our 15
probands at Scripps, we have had a successful molecular
diagnosis (using criteria as described by the Baylor group) in 8
individuals. However, establishing the diagnosis represents
only the first step of the desired strategy, as providing an effec-
tive treatment is the fundamental goal. Unfortunately, the num-
ber of individuals for whom that has been achieved is quite
limited to date, but strategies using repurposing of existing
drugs, drugs that were partially developed but not commercial-
ized, or acceleration of the development of genomically guided
therapies are all actively being pursued. With an estimate of at
least one million individuals in the United States with a serious
medical condition left without a diagnosis, such progress is
encouraging (Jacob et al., 2013).
Disease Prevention
At some point in the future, it is hoped that having DNA sequence
information will pave the way for prevention of an individual’s
predisposed conditions. To date, however, that concept has
not been actualized for a few principal reasons. First, most of
the complex, polygenic traits have not had much more than
10% of their heritability explained by the common variants as-
sessed by GWAS. The ‘‘missing’’ or unsolved heritability de-
tracts from the ability to assign an individual any certainty or
risk or protection from a particular condition. There are some
notable exceptions, such as age-related macular degeneration
or type 1 diabetes mellitus, in which combinations of common
and rare variants can provide a well-characterized, quantified
risk profile. Second, there is the appropriate question of whether
the knowledge of a risk allele is actionable. Prototypic here is
the apoε4 allele, which carries an unequivocal high risk for
Alzheimer’s disease, yet there is no proven strategy to prevent
the disease. So, even armed with known risk, there is a lack of
knowledge for how tomitigate it. Third, the way data for genomic
susceptibility are analyzed via a population approach makes it
difficult to extrapolate such average findings to a particular indi-
vidual. For example, someone may have low-frequency modifier
genes for a condition at risk or unusual environmental inter-
actions that markedly affect susceptibility. Notwithstanding
these issues, as millions of individuals with diverse phenotypes
undergo whole-genome sequencing (Figure 3), the ability to
provide meaningful risk data will increase. Having the full GIS
of each individual will further enrich the probabilistic approach
of providing vulnerability data early in one’s life. For example, if
one’s sequence data indicate a risk for hypertension, that risk
may be further modulated by knowledge of his/her proteins, me-
tabolites, microbiome, and epigenomics. The use of a biosensor
watch to passively collect continuous blood pressure measure-
ments could make diagnosis at the earliest possible time, avoid-
ing any end-organ damage to the heart or kidney. SpecificCell 157, March 27, 2014 ª2014 Elsevier Inc. 247
treatments could be used that are biologically based from one’s
GIS. Similarly, for asthma, the panoromic information, coupled
with biosensors that track air quality, pollution, forced expiratory
volume, and other relevant physiologic metrics, could prove
useful to prevent an attack.
A futuristic way in which genomics and biosensors will ulti-
mately converge is through injectable nanosensors that put the
blood in continuous surveillance mode (Ferguson et al., 2013).
Such sensors have the ability to detect a DNA, RNA, autoanti-
body, or protein signal and to wirelessly transmit the signal to
the individual’s smartphone. This sets up the potential for detect-
ing endothelial sloughing from an artery before a heart attack
(Damani et al., 2012), plasma tumor DNA in a patient being
treated for or in remission from cancer, or a child with known
genomic risk of autoimmune diabetes that is developing autoan-
tibodies to pancreatic b-islet cells long before there has been
destruction. The blood under continuous surveillance concept
highlights the potential ability to temporally detect a risk signal
for a major clinical event and to implement true preventive ther-
apy. That could be intensive antiplatelet medication to prevent a
heart attack, genomic-guided treatment of cancer recurrence at
the earliest possible juncture, or immunomodulation therapy for
autoimmune diabetes.
Infectious Diseases
Whole-genome sequencing has proven to be particularly useful
for tracking pathogen outbreaks, such as for tuberculosis (Gardy
et al., 2011), methicillin-resistant Staphylococcus aureus, antibi-
otic-resistant Klebsiella pneumonia, and Clostridium difficile
(Eyre et al., 2013; Harris et al., 2013; Snitkin et al., 2012). Beyond
identifying the particular bacterial or viral strain that accounts for
an outbreak’s origin and spread, sequencing is likely to prove to
be quite useful for rapid, early characterization of the cause of
infection and specific, effective antibiotic therapy. For sepsis,
the current standard of care is to take blood or other body fluids
for culture, which typically takes 2 days to grow out. Additionally,
there is at least another day required to determine sensitivities
to a range of antibiotics. In the future, with lab-on-a-chip
sequencing platforms that attach to or are integrated with a
smartphone (Biomeme and QuantuMD), it may be feasible to
do rapid sequencing of the pathogen and determination of the
optimal treatment. Such a strategy would preempt the need for
broad-spectrum antibiotic use, and the rapid diagnosis and tar-
geted treatment would likely have a favorable impact on prog-
nosis in these very high-risk, critically ill patients.
Cancer
With cancer’s basis in genomics, there have been extensive
efforts to characterize the principal driver mutations and biologic
pathways, especially through The Cancer Genome Atlas (TCGA)
(Kandoth et al., 2013a, 2013b; Alexandrov et al., 2013). Our un-
derstanding of the biology of cancer has expanded exponentially
and, with it, so has the appreciation for its extreme complexity.
Perhaps the two classical ‘‘Hallmarks of Cancer’’ Reviews in
Cell, one in 2000 and the sequel in 2011, best exemplify this
(Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011).
The diagram to explain the principal mechanisms of cancer
was already exceptionally complex in 2000 and became at least
a log order more intricate a decade later. In a more recent review
of the cancer genome landscape, the Johns Hopkins group pro-248 Cell 157, March 27, 2014 ª2014 Elsevier Inc.vided perspective for the 84 known oncogenes and 54 tumor
suppressor genes that have been fully validated (Vogelstein
et al., 2013). There will unquestionably be more, but estimates
of the total number of genes involved in pivotal mutations may
wind up being 200. Beyond this, the principal pathways
involving cell survival, cell fate, and DNA damage repair are
recognized. Certain cancers have a relative low burden of
mutations per megabase of the tumor genome, such as acute
myelogenous leukemia (<1), whereas other are quite high, like
lung adenocarcinoma or squamous cell carcinoma (50)
(Kandoth et al., 2013b; Vogelstein et al., 2013). Mutations of
certain genes, such as the P53 tumor suppressor, are found in
some patients with any of 12 common forms of cancer (Kandoth
et al., 2013b). Our old taxonomy of cancer based upon the organ
of origin may be considered inapt, for knowledge of the driver
mutation(s) and pathway could be more useful for individualizing
treatment. ‘‘N of 1’’ case reports with whole-genome sequencing
have been particularly illuminating for the clonal origin of an
individual’s cancer (Brannon and Sawyers, 2013; Haffner et al.,
2013). In the past 2 years, the Food and Drug Administration
has approved almost 20 new drugs that target a specific muta-
tion for cancer.
So, with these leaps in understanding biology and introduc-
tion of new therapies, why has there been relatively little impact
in the clinic to date? One major barrier is that we do not have
drugs that can target tumor suppressor genes, making up
40% of mix of principal, driver mutations. Sometimes there
are workarounds for this issue, such as the tumor suppressor
gene PTEN, which results in PI3-kinase activation, but more
often, this is not the case. Even for oncogenes, less than
40% have a specific drug antagonist, as most are part of pro-
tein complexes (Vogelstein et al., 2013). A second critical issue
is that there is marked heterogeneity in tumors, both within an
individual’s primary tumor and certainly intermetastatic. This
appears to be a foundation for the common occurrence of
relapse after an initial marked response, reflecting success
directed to an oncogene but also that other undetected muta-
tions become capable of propagating the tumor. The BRAF
mutations, which are drivers in a variety of tumors, notably
melanoma, thyroid, and colon, can be treated with a specific
BRAF inhibitor. In the first 2 weeks of oral therapy, there is usu-
ally a marked response, but at 9–12 months, a relapse is quite
typical (Sosman et al., 2012). Interestingly, when targeting
BRAF for colon cancer, there appears to be primary resistance
to these inhibitors (Prahallad et al., 2012) related to EGFR
expression and emphasizing that the stroma, microenvironment
of the tumor can still exert an important role. The issues of
heterogeneity and resistance lend credence to the use of com-
binations of targeted drugs in the future, but that has yet to be
explored at scale in prospective trials. A third largely unad-
dressed issue in the clinic is the involvement of the epigenome
in tumorigenesis. At least 40 epigenome regulator genes are
known that have highly recurrent somatic mutations in tumors
across a variety of cancers, affecting multiple target genes
simultaneously (Kandoth et al., 2013b; Vogelstein et al., 2013;
Garraway and Lander, 2013; Shen and Laird, 2013). These
are not screened for clinically, nor are there drugs available to
modulate their effect.
In the clinic today, the bare bones of mutation screening
are typically used, such as HER2 for breast cancer or KRAS for
colon cancer. Recently, Foundation Medicine commercialized
a targeted gene panel of 287 genes that have an established
role in cancer (Frampton et al., 2013). Using predominantly
fixed-formalin, paraffin-embedded samples, mutation cell con-
cordance was established compared with mass spectrometric
methodology (Sequenom), and the typical driver mutations
were identified in a cohort of more than 2,000 individuals, such
as TP53, KRAS, CDKN2A, and PIK3CA (Frampton et al., 2013).
However, there was a long tail of uncommon mutations that
was identified, reflecting the profound diversity of cancers.
This panel represents a step forward compared with a very
limited gene mutation screen for commonly occurring drivers,
which might even miss other pathogenic mutations within
incriminated genes. The 287 genes assessed represent only
<15% of genes and only the coding elements. This is in contrast
to research studies of whole-genome and whole-exome
sequencing, with paired germline DNA for each individual, to
more precisely determine driver mutations (Kandoth et al.,
2013b). Further, multiple recent studies have highlighted the
role of noncoding elements of the genome to play a prominent
role, such as TERT promoters in melanoma (Huang et al.,
2013), a long, noncoding RNA SChLAP1 for aggressive prostate
cancer (Prensner et al., 2013), and identification of 100 non-
coding driver variants for cancer using a new bioinformatics
tool known as FunSeq (Khurana et al., 2013). Clearly, even a
comprehensive exome would only represent a limited swath of
sampling for root causes of cancer in an individual.
Cancer genomic medicine of the future will likely involve a GIS
of the tumor with assessment of DNA sequence, gene expres-
sion, RNA-seq, microRNAs, proteins, copy number variations,
and DNA methylation cross-referenced with the individual’s
germline DNA. But the issue of addressing heterogeneity still
looms (Vogelstein et al., 2013; Bedard et al., 2013), and for
that, there are a few possible steps, including deep sequencing
of the tumor at multiple locations, single-cell sequencing, or the
use of the ‘‘liquid biopsy’’ of cancer (Schwarzenbach et al., 2011;
Leary et al., 2010; Forshew et al., 2012).
Cell-free tumor DNA in plasma, which is present in the vast
majority of patients with cancer, has been shown to be a useful
biomarker for following patients (Schwarzenbach et al., 2011;
Leary et al., 2010; Forshew et al., 2012) and appears to have
independent prognostic significance (Dawson et al., 2013). It
may be that plasma tumor DNA is the best representative
of the cancer for targeted treatment because avoidance of
metastasis is of utmost concern. The ease of isolating and
sequencing cell-free tumor DNA is likely to make this a very
attractive and routine in the future. Especially appealing is the
ability to sample on a more frequent and even continuous basis
using biosensors. Whether the ‘‘liquid biopsy’’ will help override
the challenges related to intratumor heterogeneity and re-
currence of cancer awaits prospective evaluation. Also of
particular interest, at some point, will be screening healthy peo-
ple for cell-free tumor DNA to determine whether we are
constantly facing microscopic tumor burden but are able
to effectively keep the disease in check by a variety of homeo-
static mechanisms.Molecular Diagnosis
When a patient receives a diagnosis of a chronic illness today, it
is nonspecific and is based on clinical and not molecular
features. Take, for example, diabetes mellitus type 2, which
could reflect anything from insulin resistance, failure of b-islet
cells, or a variety of subtypes, including a-adrenergic receptor
(ADRA2A) diabetes (Gribble, 2010) or a zinc transporter subtype
(SLC30A8) (Sladek et al., 2007). Common genomic variants have
been identified in pathways involving signal transduction, cell
proliferation, glucose sensing, and circadian rhythm (Dupuis
et al., 2010). Some individuals with a high fasting glucose have
a G6PC2 variant that is associated with protection from diabetes
(Bouatia-Naji et al., 2008). A genotype score, amalgamating the
number of risk variants, has been shown to be helpful for identi-
fying high susceptibility (Meigs et al., 2008). Moreover, there are
13 classes of drugs to treat diabetes, and the treatment could be
made considerably more rational with knowledge of the individ-
ual’s underlying mechanism(s).
This brief summary of the diabetes example reflects the need
for a new molecular taxonomy across all diseases. When an
individual is diagnosed (or at some point when risk can be
defined), the molecular basis will be assessed and, ideally,
when possible, the root cause will be established. Clearly, for
many common diseases, there are multiple pathways impli-
cated, and this may prove to be difficult. But there has yet to
be a systematic attempt of providing such amolecular diagnosis
in clinical care. Despite multiple reports of molecular subtypes of
asthma (Wenzel, 2012), multiple sclerosis (Ottoboni et al., 2012),
and colon (Sadanandam et al., 2013) and uterine cancer (Kan-
doth et al., 2013a), which appear to be linked with therapy and
prognosis, this has yet to be made part of medical practice.
Pharmacogenomics
Just as molecular subtyping of chronic disease is not part of
medical practice, pharmacogenomics screening for either
assurance of efficacy or avoidance of major side effects is
predominantly ignored. With the use of GWAS, there has been
an avalanche of discovery of alleles that are pivotal to individual
drug response. Unlike polygenic disease, for which the pene-
trance for a common sequence variant is quite low (approximate
odds ratio of 1.15), the typical genotype odds ratio for prescrip-
tion drugs can be as high as 80, and for many, the range is 3- to
40-fold (reviewed in depth in Harper and Topol [2012]). The likely
explanation for this pronounced impact of common variants on
individual drug response is based on selection—as compared
with diseases, the human genome has had very limited time to
adapt to medication exposure. Despite there being more than
100 drugs that carry a genomic ‘‘label’’ by the Food and Drug
Administration, meaning that there is a recommendation for
genotype assessment before the drug is used, there is rarely
any pharmacogenomic assessment in clinical practice. This
needs to improve, and perhaps the availability of point-of-care
testing will help, along with reduced cost, to eventually promote
routine use. Beyond this barrier, there needs to bemore genomic
sequencing for commonly used drugs, with associated pheno-
typic determination of efficacy and side effects, along with sys-
tematic omic assessment for drugs in development. From the
marked success of discovering genomic-drug interactions found
to date, there is certainly the sense that, the more you look, theCell 157, March 27, 2014 ª2014 Elsevier Inc. 249
more you will find. The potential here is to reduce the waste of
pharmaceuticals, not just by avoiding drugs that will not provide
efficacy for particular individuals but also by avoiding serious
toxicity that can be either fatal or life threatening.
Healthspan
The human reference genome is based upon multiple young
individuals who had no phenotypic characterization. Accord-
ingly, we know nothing about the reference human’s natural
history of disease, and one can consider this as a flawed
standard for comparison. Ideally, we should have a reference
genome that has had rigorous phenotyping. This is especially
the case in an era of using sequencing in medical practice but
with an inadequate comparator. Perhaps the optimal phenotype
would be healthspan. At Scripps, we have defined healthy
elderly as age >80 years with no history of chronic illness or
use of medications. The cohort (known as ‘‘Wellderly’’) that we
have assembled over the past 7 years of 1,400 individuals has
an average age of 88, and we have completed whole-genome
sequencing for 500 of these individuals. The intent is to provide
a more useful reference genome with a clearly defined, uniform,
and relevant phenotype.
Moreover, there is another important application of healthspan
genomics. Multiple studies have established that a research
investment in understanding healthy aging would be more pru-
dent than in any specific disease category (Goldman et al.,
2013a). Because the cohort that we have enrolled carries a
similar burden of common risk variants for chronic diseases
compared with the general population, there are most likely a
substantial number of modifier genes and protective alleles
that may be ultimately identified. One example is from APP, a
gene that has a variant for both high risk of Alzheimer’s and
another rare variant with marked protection from cognitive
impairment of Alzheimer’s (De Strooper and Voet, 2012). Un-
questionably, there are many more such variants left to be
discovered, and therein lies the potential for drug discovery
efforts that can follow such findings from nature of particular
genes and pathways that prevent diseases.
Molecular Autopsies
Although physical autopsies have lost favor and become excep-
tionally rare, there is an opportunity to use sequencing to deter-
mine the cause of death, particularly when this occurs suddenly.
Targeted or whole-genome sequencing for heritable heart
disorders implicated in sudden death, including ion channel
mutations and hypertrophic cardiomyopathy, can be performed
in the deceased individual and family members. This approach is
now actively being pursued in New York City for all sudden
cardiac deaths (Erdmann, 2013) and may prove helpful in pre-
venting this condition in family members.
Future Directions
This prewomb-to-tomb review has emphasized that there is a
disproportionate relationship between knowledge and imple-
mentation into clinical practice. For individualized medicine to
take hold, it will require intensive, rigorous validation that these
new approaches improve patient outcomes and are demon-
strated to be cost effective. This proof will be essential for the
medical community to embrace the opportunities but will also
require educational programs that squarely address the knowl-
edge chasm that currently exists for practicing physicians. A250 Cell 157, March 27, 2014 ª2014 Elsevier Inc.second theme is that our efforts have been largely sequence
centric and have not adequately taken into account or integrated
the data from other omics, no less biosensors and imaging.
Related to this deficiency, there is a profound shortage of data
scientists in biomedicine, with unparalleled opportunities to
process enormous, high-yield data sets. While we will increas-
ingly rely on algorithms, artificial intelligence, and machine
learning, the rate-limiting step necessitates talented bio-
computing and bioinformatic human expertise.
One of the most attractive outgrowths of defining each in-
dividual’s unique biology in an era with unprecedented digital
infrastructure is to be able to share the data. By taking the
deidentified data from each individual, including panoromic, bio-
sensors, social graph, treatment, and outcomes, an extra-
ordinary resource can now be developed. Such a massive
open online medical information (MOOM) repository could
provide matching capability to approximate a newly diagnosed
individual’s data as compared with all of those previously amal-
gamated. For a patient with cancer, for example, this could
provide closest matches to the tumor GIF, demographics, treat-
ment, and outcomes to select an optimal strategy; this would
potentially take Bayesian principles to a new, enriched potential.
Such aMOOM resource does not need to be confined to cancer,
but the first to be announced was with the Leukemia & Lym-
phoma Society and Oregon Health Sciences University for 900
patients with liquid tumors (Winslow, 2013). Hopefully, this will
be one of many data-sharing initiatives in medicine to go for-
ward, now that such rich unique information can be captured
at the individual level, and our computing infrastructure is so
well suited to perform such functions. Although we are still at
the nascent stages of individualized medicine, there has never
been more promise and opportunity to reboot the way health
care can be rendered. Only with systematic validation of these
approaches at the intersection of biology and digital technology
canwe actualize thismore precise, futuristic version ofmedicine.
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